Recurring Translocations in Barrett's Esophageal Adenocarcinoma

Area of Science:

• Oncology
• Genetics
• Gastroenterology

Background:

• Barrett's esophagus (BE) is a precancerous condition linked to chronic GERD.
• BE can advance to esophageal adenocarcinoma (EA), a cancer with poor survival rates.
• Early detection of chromosomal abnormalities in BE is crucial for identifying malignant potential.

Purpose of the Study:

• To identify novel chromosomal alterations in early-stage Barrett's epithelial carcinogenesis.
• To develop a diagnostic assay for detecting these chromosomal changes in esophageal adenocarcinoma.
• To validate the assay's feasibility in detecting chromosomal events in primary tumor tissues.

Main Methods:

• Utilized an in vitro model of acid and bile exposure-induced Barrett's epithelial carcinogenesis.
• Employed fluorescence microscopy to refine chromosomal translocation events.
• Developed and validated a fluorescent in situ hybridization for esophageal adenocarcinoma (FISH-EA) assay.

Main Results:

• Identified a novel recurring three-way chromosomal translocation, t(2:10;16) (p22;q22;q22), in BE cells prior to malignant transformation.
• The FISH-EA assay successfully detected chromosomal breakpoints and fusions.
• Confirmed the presence of a fusion in paraffin-embedded human EA tumors, validating the assay's feasibility.

Conclusions:

• The t(2:10;16) translocation is a potential early biomarker for esophageal adenocarcinoma progression from Barrett's esophagus.
• The FISH-EA assay offers a promising tool for objective detection of these chromosomal events.
• Further clinical validation is needed to establish the assay's sensitivity and specificity in identifying malignant potential.